Phellodendron and Citrus extracts benefit cardiovascular health in osteoarthritis patients: A double-blind, placebo-controlled pilot study

Nutrition Journal

Volumn 7, Issue 1, 2008, Pages

  Oben, Julius ^a   Enonchong, Ebangha ^a   Kothari, Shil ^b   Chambliss, Walter ^c   Garrison, Robert ^d   Dolnick, Deanne ^d  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b Gateway Health Alliances Inc   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d Next Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRUS EXTRACT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NP 06 1; PHELLODENDRON AMURENSE EXTRACT; PLACEBO; PLANT EXTRACT; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORK TREE; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; KNEE OSTEOARTHRITIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SWEET ORANGE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHEMISTRY; CITRUS FRUIT; DIET SUPPLEMENTATION; DRUG EFFECT; LIPID METABOLISM; MIDDLE AGED; OSTEOARTHRITIS; PHYSIOLOGY; PILOT STUDY; TREATMENT OUTCOME; WEIGHT REDUCTION;

CITRUS; CITRUS SINENSIS; PHELLODENDRON; PHELLODENDRON AMURENSE;

ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CITRUS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; OSTEOARTHRITIS; OVERWEIGHT; PHELLODENDRON; PILOT PROJECTS; PLANT EXTRACTS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 44849108185     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/1475-2891-7-16     Document Type: Article

References (16)

1. Strategies for the prevention and management of osteoarthritis of the hip and knee. JW Bijlsma K Knahr, Best Pract Res Clin Rheumatol 2007 21 1 59 76 10.1016/j.berh.2006.08.013 17350544
2. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. LG Ameye WS Chee, Arthritis Res Ther 2006 8 4 R127 16859534 10.1186/ar2016
3. Herbal medicines for the treatment of osteoarthritis: a systematic review. L Long K Soeken E Ernst, Rheumatology 2001 40 779 793 10.1093/rheumatology/40.7.779 11477283
4. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. R Christensen EM Bartels A Astrup H Bliddal, Ann Rheum Dis 2007 66 4 433 9 10.1136/ard.2006.065904 17204567
5. Central obesity and the metabolic syndrome: implications for primary care providers. SJ Appel ED Jones L Kennedy-Malone, J Am Acad Nurse Pract 2004 16 8 335 342 10.1111/j.1745-7599.2004.tb00456.x 15455706
6. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. W Kong J Wei P Abidi M Lin S Inaba C Li Y Wang Z Wang S Si H Pan S Wang J Wu Y Wang Z Li J Liu JD Jiang, Nat Med 2004 10 12 1344 51 10.1038/nm1135 15531889
7. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. AF Cicero LC Rovati I Setnikar, Arzneimittelforschung 2007 57 1 26 30 17341006
8. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. JM Brusq N Ancellin P Grondin R Guillard S Martin Y Saintillan M Issandou, J Lipid Res 2006 47 6 1281 8 10.1194/jlr.M600020-JLR200 16508037
9. Hypolipidemic effects and absorption of citrus polymethoxylated flavones in hamsters with diet-induced hypercholesterolemia. EM Kurowska JA Manthey, J Agric Food Chem 2004 52 10 2879 86 10.1021/jf035354z 15137829
10. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. NJ Stone S Bilek S Rosenbaum, Am J Cardiol 2005 96 4A 53E 59E 10.1016/j.amjcard.2005.06.006 16098845
11. Prompt, aggressive BP lowering in high-risk patients. KA Jamerson J Basile, J Clin Hypertens (Greenwich) 2008 10 1 Suppl 1 40 8 10.1111/j.1524-6175. 2007.08145.x 18174783
12. Management of obesity in patients with type 2 diabetes mellitus. L Gagliardi G Wittert, Curr Diabetes Rev 2007 3 2 95 10 10.2174/157339907780598207 18220660
13. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. YS Lee WS Kim KH Kim MJ Yoon HJ Cho Y Shen JM Ye CH Lee WK Oh CT Kim C Hohnen-Behrens A Gosby EW Kraegen DE James JB Kim, Diabetes 2006 55 8 2256 64 10.2337/db06-0006 16873688
14. Citrus polymethoxylated flavones improve lipid and glucose homeostasis and modulate adipocytokines in fructose-induced insulin resistant hamsters. Li RW Li AG Theriault K Au TD Douglas A Casaschi EM Kurowska R Mukherjee, Life Sci 2006 79 4 365 73 10.1016/j.lfs.2006.01.023 16497336
15. Modulation of Hepg2 cell net apolipoprotein B secretion by the Citrus polymethoxyflavone, tangeretin. EM Kurowska JA Manthey A Casaschi AG Theriault, Lipids 2004 39 2 143 151 15134141
16. Nobiletin, a citrus flavonoid isolated from tangerines, selectively inhibits class A scavenger receptor-mediated metabolism of acetylated LDL by mouse macrophages. SC Whitman EM Kurowska JA Manthey A Daugherty, Atherosclerosis 2005 178 1 25 32 10.1016/j.atherosclerosis.2004.07.034 15585197